| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1002/DA.20884 |
| P698 | PubMed publication ID | 21898710 |
| P50 | author | Fadi T Maalouf | Q126688351 |
| Mia Atwi | Q126708482 | ||
| P2093 | author name string | David A Brent | |
| P2860 | cites work | Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study | Q24607463 |
| Cognitive-behavioral therapy for suicide prevention (CBT-SP): treatment model, feasibility, and acceptability | Q24632459 | ||
| Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial | Q24669688 | ||
| A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report | Q28261272 | ||
| Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies | Q30782407 | ||
| Treatment response in depressed adolescents with and without co-morbid attention-deficit/hyperactivity disorder in the Treatment for Adolescents with Depression Study | Q33694973 | ||
| Mechanism underlying the therapeutic effects of electroconvulsive therapy (ECT) on depression | Q33720006 | ||
| Remission and recovery in the Treatment for Adolescents with Depression Study (TADS): acute and long-term outcomes | Q33745342 | ||
| Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study | Q33919579 | ||
| Substance use and the treatment of resistant depression in adolescents | Q33956890 | ||
| Neurocognitive impairment in adolescent major depressive disorder: state vs. trait illness markers | Q33992755 | ||
| Medication augmentation after the failure of SSRIs for depression. | Q33994373 | ||
| Symptom improvement and residual symptoms during acute antidepressant treatment in pediatric major depressive disorder | Q34315319 | ||
| Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial | Q34341755 | ||
| Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. | Q34447980 | ||
| Acute and long-term VNS effects on pain perception in a case of treatment-resistant depression. | Q51128684 | ||
| Repetitive transcranial magnetic stimulation in the treatment of depression in adolescents: an open-label study. | Q51889239 | ||
| Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS). | Q51909487 | ||
| Remissions in maternal depression and child psychopathology: a STAR*D-child report. | Q51920061 | ||
| Psychiatric disorder and metabolic control among youths with IDDM. A longitudinal study. | Q52008543 | ||
| Tranylcypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report | Q57616045 | ||
| Antidepressants and adolescents: the bipolar confound? | Q59210432 | ||
| Lithium Antidepressant Augmentation in TCA-refractory Depression in Adolescents | Q68392640 | ||
| Bipolar illness in adolescents with major depression: clinical, genetic, and psychopharmacologic predictors in a three- to four-year prospective follow-up investigation | Q70392247 | ||
| Rate and predictors of prepubertal bipolarity during follow-up of 6- to 12-year-old depressed children | Q72000594 | ||
| Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder | Q73347318 | ||
| Executive dysfunction predicts nonresponse to fluoxetine in major depression | Q74162961 | ||
| VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms. | Q34518168 | ||
| Practice parameter for use of electroconvulsive therapy with adolescents | Q34552856 | ||
| Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents | Q34613195 | ||
| Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials | Q34619977 | ||
| Practice parameter for the assessment and treatment of children and adolescents with depressive disorders | Q34720078 | ||
| Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials | Q34997918 | ||
| Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes | Q35671518 | ||
| Effects of psychotherapy for depression in children and adolescents: what we can (and can't) learn from meta-analysis and component profiling | Q36293420 | ||
| Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial | Q36514240 | ||
| Treatment-resistant depression in adolescents: recognition and management | Q36585514 | ||
| Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS). | Q36669012 | ||
| Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) study | Q36703044 | ||
| An exploratory analysis of the impact of family functioning on treatment for depression in adolescents | Q36720893 | ||
| Effective components of TORDIA cognitive-behavioral therapy for adolescent depression: preliminary findings | Q36995113 | ||
| Pharmacogenomics with antidepressants in the STAR*D study | Q37205961 | ||
| Suicidal events in the Treatment for Adolescents With Depression Study (TADS). | Q37243110 | ||
| Brief interpersonal psychotherapy for depressed mothers whose children are receiving psychiatric treatment | Q37377095 | ||
| The role of pharmacogenetics in the treatment of depression and anxiety disorders | Q37593913 | ||
| Combined treatment with cognitive-behavioural therapy in adolescent depression: meta-analysis | Q37813906 | ||
| Pulse intravenous clomipramine for depressed adolescents: double-blind, controlled trial | Q39456259 | ||
| Cross-sectional and prospective relationships between physical morbidity and depression in older adolescents | Q40929469 | ||
| Family risk factors for child and adolescent suicidal behavior | Q41430082 | ||
| Half a century of ECT use in young people | Q41459752 | ||
| Treatment strategy in depression. II. MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine | Q41814649 | ||
| The Treatment for Adolescents With Depression Study (TADS): outcomes over 1 year of naturalistic follow-up | Q43282331 | ||
| The pharmacotherapy of depressive illness in adolescence: II. Effects of lithium augmentation in nonresponders to imipramine | Q43542553 | ||
| Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression | Q43565910 | ||
| Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. | Q44097670 | ||
| Open Trial of Bupropion SR in Adolescent Major Depression | Q44646126 | ||
| Age effects on antidepressant-induced manic conversion | Q45003904 | ||
| Treated depression in adolescents: predictors of outcome at 28 weeks | Q46066566 | ||
| A controlled study of repetitive transcranial magnetic stimulation in medication-resistant major depression | Q46684565 | ||
| Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders | Q46722137 | ||
| Adjunctive quetiapine for treatment-resistant adolescent major depressive disorder: a case series | Q46725725 | ||
| Effects of electroconvulsive therapy in adolescents with severe endogenous depression resistant to pharmacotherapy | Q46787265 | ||
| Clinical and psychosocial predictors of suicide attempts and nonsuicidal self-injury in the Adolescent Depression Antidepressants and Psychotherapy Trial (ADAPT). | Q47293420 | ||
| Predictors of treatment efficacy in a clinical trial of three psychosocial treatments for adolescent depression | Q47349331 | ||
| The symptomatic expression of major depressive disorder in adolescents and young adults | Q47863501 | ||
| Development of the cerebral cortex: XI. Sexual dimorphism in the brain | Q48354548 | ||
| Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS). | Q48484015 | ||
| Cingulate function in depression: a potential predictor of treatment response | Q48768060 | ||
| Major depressive disorder in older adolescents: prevalence, risk factors, and clinical implications. | Q50856088 | ||
| Fluoxetine in child and adolescent depression: acute and maintenance treatment. | Q51097644 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | treatment-resistant depression | Q7836891 |
| teenager | Q1492760 | ||
| P304 | page(s) | 946-954 | |
| P577 | publication date | 2011-09-02 | |
| P1433 | published in | Depression and Anxiety | Q15716773 |
| P1476 | title | Treatment-resistant depression in adolescents: review and updates on clinical management | |
| P478 | volume | 28 |
| Q35230777 | Abnormal amygdala resting-state functional connectivity in adolescent depression |
| Q43259449 | Adjunctive Trazodone and Depression Outcome in Adolescents Treated with Serotonin Re-uptake Inhibitors |
| Q27323164 | Behavioural profiles in captive-bred cynomolgus macaques: towards monkey models of mental disorders? |
| Q34849885 | Cortical shape and curvedness analysis of structural deficits in remitting and non-remitting depression |
| Q28658916 | Depressive-like behavioral profiles in captive-bred single- and socially-housed rhesus and cynomolgus macaques: a species comparison |
| Q91669829 | Internet Addiction and Depression in Chinese Adolescents: A Moderated Mediation Model |
| Q89527723 | Ketamine: The final frontier or another depressing end? |
| Q38247062 | Management of treatment-resistant depression in children and adolescents |
| Q60637498 | Psychopharmakologische Behandlung von Depressionen im Kindes- und Jugendalter |
| Q30547324 | Repeated ketamine exposure induces an enduring resilient phenotype in adolescent and adult rats |
| Q42131869 | Seizure Induced by Deep Transcranial Magnetic Stimulation in an Adolescent with Depression |
| Q26865021 | Systematic review of management for treatment-resistant depression in adolescents |
| Q38153379 | The Iowa Gambling Task in depression - what have we learned about sub-optimal decision-making strategies? |
| Q37562007 | The use of cognitive behavioral therapy in the treatment of resistant depression in adolescents |
| Q36523746 | Treatment resistant adolescent depression with upper airway resistance syndrome treated with rapid palatal expansion: a case report |
| Q35997448 | Treatment-resistant depression: therapeutic trends, challenges, and future directions |
Search more.